Vimta Labs
664.15
+4.55(+0.69%)
Market Cap₹2,935.60 Cr
PE Ratio48.34
IndustryHealthcare
Company Performance:
1D+0.69%
1M+26.42%
6M+43.01%
1Y+168.04%
5Y+1,096.02%
View Company Insightsright
Latest news about Vimta Labs
Vimta Labs Reports Record Q1 Revenue of INR 993 Million, Up 31.4% Year-on-Year Jul 25, 2025
Vimta Labs Limited achieved its highest ever quarterly revenue of INR 993.00 million in Q1 FY2026, a 31.4% year-on-year increase. EBITDA rose by 33.1% to INR 354.00 million, with a margin of 35.7%. Profit After Tax grew by 35.9% to INR 189.00 million. The company successfully passed a US FDA GCP inspection, received cGMP compliance from ANSM EMA, and approved a 1:1 bonus issue. Vimta Labs expanded its facility by 200,000 square feet and maintains a debt-free balance sheet with INR 379.30 million in cash equivalents. The company is progressing with equipment procurement for biologics contract research services, expected to launch in Q1 FY2027.
Vimta Labs Reports 35% Surge in Q1 Net Profit, Revenue Up 31%, EBITDA Grows Jul 17, 2025
Vimta Labs Reports Strong FY25 Results, Targets Revenue of Over Rs. 500 Crore by FY 2025-26 Apr 28, 2025
Vimta Labs Announces 1:1 Bonus Share Issue and Strong Financial Performance Apr 28, 2025
More news about Vimta Labs
28Apr 25
Vimta Labs Reports Strong Q4 FY25 Results, Announces Bonus Shares and Expansion into Biologics
Vimta Labs reported robust Q4 and FY25 results with total income reaching ₹3,482.22 crore, up 19.1% year-on-year. Q4 FY25 saw a 31.4% increase in total income to ₹960.81 crore. The company declared a final dividend of ₹2 per share and recommended a 1:1 bonus share issue. Strategic initiatives include a ₹50 crore investment in Biologics CDMO, increased borrowing powers to ₹300 crore, and reappointment of Dr. Yadagiri R Pendri as Independent Director. Operational highlights include successful regulatory audits and expansion of laboratory spaces.
23Apr 25
Vimta Labs to Consider Q4 Results, Dividend, and Bonus Share Issue on April 28
Vimta Labs Limited has scheduled a board meeting for April 28, 2025, to approve Q4 and FY2025 financial results, consider dividend payment, and discuss a potential bonus share issue. The company has implemented a trading window closure from April 1, 2025, until 48 hours after the financial results announcement, in compliance with SEBI regulations.
Vimta Labs
664.15
+4.55
(+0.69%)
1 Year Returns:+168.04%
Industry Peers
Syngene International
663.65
(-0.59%)
Indegene
588.00
(+2.68%)
Suven Life Sciences
231.20
(-1.70%)
Vimta Labs
664.15
(+0.69%)
Bilcare
66.02
(-1.33%)
Take Solutions
10.01
(+4.93%)
Adeshwar Meditex
18.00
(0.0%)
Vanta Bioscience
25.64
(0.0%)